Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim of this study is evaluation of vitamin D as a agent that can reduce fertility complications of chemotherapy specially in young women.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Women aged 18 to 45 years old, undergoing adjuvant or neoadjuvant chemotherapy due to breast cancer from 2018 to 2019 at Imam Khomeini Cancer Institute were included as the intervention group to this study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The protective effect of vitamin D on ovarian reserve and anti‐mullerian hormone in patients undergoing chemotherapy for breast cancer, a randomized phase ΙΙ clinical trial

Study design awaiting verification · Cancer Reports · 2024

Original publication title

The protective effect of vitamin D on ovarian reserve and anti‐mullerian hormone in patients undergoing chemotherapy for breast cancer, a randomized phase ΙΙ clinical trial

Zahra Dastmardi; Marzieh Lashkari; Arefeh Saeedian; Mahdi Aghili; Sadaf Alipour

© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Despite a minimal rise in the AMH level after six months of chemotherapy, the study could not demonstrate any protective effect of vitamin D on patients' ovarian reserve undergoing chemotherapy for breast cancer. Further larger studies are needed to evaluate the effect of vitamin D supplements on ovarian reserve beside optimal dose and duration.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

The aim of this study is evaluation of vitamin D as a agent that can reduce fertility complications of chemotherapy specially in young women.

Source: Aim

Abstract: What methods does the paper describe?

Breast cancer patients undergoing chemotherapy at two cancer institutes were enrolled in this study. The case group received 1000 IU of calcitriol, and the AMH level was measured at the baseline, after chemotherapy, and six months after chemotherapy. The primary end point was improvement in the AMH level after six months of chemotherapy. the secondary endpoint was to evaluate the predictive factors of AMH level decline during chemotherapy.

Source: Methods

Abstract: Results

Between 2018 and 2019, 18 and 15 patients were enrolled in the case and control groups, respectively. The mean AMH level (ngr/ml) of the patients in the case and control group were 3.16 and 2.37 ng/mL, respectively (p‐value = .16). These levels were 0.387 and 0.19 after six months (p‐value = .38). The AMH rise immediately after chemotherapy cycles to six months after chemotherapy, in the case and control groups were 0.86 and 0.44 ng/mL, respectively, which was slightly higher in the case group but not statistically significant between two groups (p‐value = .054).

Source: Results

Abstract: Conclusion

Despite a minimal rise in the AMH level after six months of chemotherapy, the study could not demonstrate any protective effect of vitamin D on patients' ovarian reserve undergoing chemotherapy for breast cancer. Further larger studies are needed to evaluate the effect of vitamin D supplements on ovarian reserve beside optimal dose and duration.

Source: Conclusion
Authors’ abstract

Abstract

Background

Reduced ovarian reserve is among the crucial long‐term side effects of using chemotherapy agents in breast cancer, yielding early ovarian failure. On the other hand, vitamin D is an essential factor in protecting the follicles and an important predictive factor for successful IVF therapy.

Aim

The aim of this study is evaluation of vitamin D as a agent that can reduce fertility complications of chemotherapy specially in young women.

Methods

Breast cancer patients undergoing chemotherapy at two cancer institutes were enrolled in this study. The case group received 1000 IU of calcitriol, and the AMH level was measured at the baseline, after chemotherapy, and six months after chemotherapy. The primary end point was improvement in the AMH level after six months of chemotherapy. the secondary endpoint was to evaluate the predictive factors of AMH level decline during chemotherapy.

Results

Between 2018 and 2019, 18 and 15 patients were enrolled in the case and control groups, respectively. The mean AMH level (ngr/ml) of the patients in the case and control group were 3.16 and 2.37 ng/mL, respectively (p‐value = .16). These levels were 0.387 and 0.19 after six months (p‐value = .38). The AMH rise immediately after chemotherapy cycles to six months after chemotherapy, in the case and control groups were 0.86 and 0.44 ng/mL, respectively, which was slightly higher in the case group but not statistically significant between two groups (p‐value = .054).

Conclusion

Despite a minimal rise in the AMH level after six months of chemotherapy, the study could not demonstrate any protective effect of vitamin D on patients' ovarian reserve undergoing chemotherapy for breast cancer. Further larger studies are needed to evaluate the effect of vitamin D supplements on ovarian reserve beside optimal dose and duration.

Publication and source details

Original title: The protective effect of vitamin D on ovarian reserve and anti‐mullerian hormone in patients undergoing chemotherapy for breast cancer, a randomized phase ΙΙ clinical trial

Zahra Dastmardi; Marzieh Lashkari; Arefeh Saeedian; Mahdi Aghili; Sadaf Alipour

Cancer Reports · 2024

* Correspondence
Marzieh Lashkari, Radiation Oncology Research Center, Radio‐Oncology Ward, Cancer Institute, Qarib Street, Keshavarz Blvd., Tehran, Iran.
Email: m-lashkari@tums.ac.ir
© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:24:55.837648+00:00

DOI: 10.1002/cnr2.2104 · PMC11194676